// App-Quantinova.ai

AB0433 (2022) : ANTI-RITUXIMAB ANTIBODIES DEMONSTRATE NEUTRALISING CAPACITY, ASSOCIATE WITH LOWER CIRCULATING DRUG LEVELS AND EARLY RELAPSE IN PATIENTS UNDERGOING TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Researchers

Presenter

  • C. Wincup

Principal Investigators

  • N. Dunn

  • C. Ruetsch-Chelli

  • A. Manouchehrinia

  • N. Kharlamova

  • M. Naja

  • B. Seitz-Polski

  • D. Isenberg

  • A. Fogdell-Hahn

  • C. Ciurtin

  • E. Jury

Medical Centers

  • University College London, Gastroenterology, London, United Kingdom

  • Karolinska Institutet, Department of Clinical Sciences Danderyd, Stockholm, Sweden

  • Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden

  • Université Côte d’Azur, Laboratoire d’Immunologie, Nice, France

  • Université Côte d’Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France

  • Université Côte d’Azur, Unité de Recherche Clinique de la Côte d’Azur (UR2CA), Nice, France

Locations

  • United Kingdom

  • Sweden

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved